President Barack Obama's proposals to reduce the exclusivity period for brand-name biologic drugs from 12 years to seven and to extend drugmaker rebates under Medicaid to Medicare drew harsh criticism from the Pharmaceutical Research and Manufacturers of America. The proposals will drive up drug prices and discourage investment in the biotech sector, PhRMA President John Castellani said.

Related Summaries